DER Reference Model Version 1.0.0
ecqm.measure

CMS136v8 - Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Rationale:

Follow-Up Care for Children Prescribed ADHD Medication (ADD). Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent behavioral health diseases in children. A National Survey of Children's Health study found that, in 2007, about 9.5% of children 4 to 17 years of age, or about 5.4 million, had a history of ADHD (CDC 2010). Of those 5.4 million children with a history of ADHD, 78% had a current diagnosis of ADHD at the time of the survey (CDC 2010) and 66.3% of those children were taking medication for the disorder (CDC 2010). A similar survey conducted in 2013 found that about 10% of American children age 3-17 have been diagnosed with ADHD (Bloom et al., 2013). ADHD also incurs substantial financial costs due to medical care and work loss costs for patients and families. The annual average direct cost per ADHD patient is $1,574 dollars compared to $541 dollars among similar individuals without ADHD (Swensen et al. 2003). Additionally, children with ADHD add a higher cost to the education system - on average $5,000 each year for each student with ADHD (Robb et al., 2011). There are many symptoms associated with ADHD. Children with ADHD may experience significant functional problems, such as school difficulties, academic underachievement, troublesome relationships with family members and peers and behavioral problems (American Academy of Pediatrics 2000). For instance, recent studies have found that parents whose children have a history of ADHD report significantly more peer problems and a higher rate of non-fatal injuries compared to parents whose children do not have a history of ADHD (Strine et al. 2006; Xiang et al. 2005). Additional studies suggest that there is an increased risk for drug use disorders in adolescents with untreated ADHD (National Institute on Drug Abuse, 2010). One of the national objectives of the Department of Health and Human Services Healthy People 2020 initiative is to increase the proportion of children with mental health problems who receive treatment. Medication treatment has been found to be effective for managing ADHD, but treatment requires careful monitoring by physicians. Studies have shown that psychostimulants are highly effective for 75-90% of children with ADHD by reducing symptoms of hyperactivity, impulsivity and inattention; improving classroom performance and behavior; and promoting increased interaction with teachers, parents and peers (U.S. Department of Health and Human Services 1999). Some reported adverse effects of stimulant ADHD medications including appetite loss, abdominal pain, headaches, sleep disturbance, decreasing growth velocity, and less commonly, hallucinations and other psychotic symptoms (Wolraich et al. 2011). Therefore, it is important to assess the presence or absence of potential adverse effects before and after a stimulant drug is initiated (Smucker & Hedayat 2001). Monitoring adverse effects from ADHD medication allows physicians to suggest an optimal, alternative treatment. Studies have also shown that treating children with effective medication management can lead to substantially greater improvements in social skills and peer relations compared to children who are not effectively managed (Jensen et al. 2001). Finally, treatments for children with ADHD are frequently not sustained despite the fact that they are at greater risk of significant problems if they discontinue treatment (Wolraich et al. 2011). Effective management mitigates the risk of discontinuing treatment.